188 related articles for article (PubMed ID: 37672282)
1. Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma.
Bateni SB; Nguyen P; Eskander A; Seung SJ; Mittmann N; Jalink M; Gupta A; Chan KKW; Look Hong NJ; Hanna TP
JAMA Dermatol; 2023 Nov; 159(11):1195-1204. PubMed ID: 37672282
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
[TBL] [Abstract][Full Text] [Related]
3. Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016.
Brastianos HC; Nguyen P; Sahgal A; Eisenhauer EA; Baetz T; Hanna TP
JAMA Netw Open; 2020 Jul; 3(7):e208204. PubMed ID: 32663310
[TBL] [Abstract][Full Text] [Related]
4. Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma.
Tawbi H; Bartley K; Seetasith A; Kent M; Lee J; Burton E; Haydu L; McKenna E
J Manag Care Spec Pharm; 2022 Mar; 28(3):342-353. PubMed ID: 35199578
[No Abstract] [Full Text] [Related]
5. Trajectories of Health Care Contact Days for Patients With Stage IV Non-Small Cell Lung Cancer.
Gupta A; Nguyen P; Kain D; Robinson AG; Kulkarni AA; Johnson DH; Presley CJ; Blaes AH; Rocque GB; Ganguli I; Booth CM; Hanna TP
JAMA Netw Open; 2024 Apr; 7(4):e244278. PubMed ID: 38587847
[TBL] [Abstract][Full Text] [Related]
6. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
Lamba N; Ott PA; Iorgulescu JB
JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
[TBL] [Abstract][Full Text] [Related]
7. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
8. Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease.
Erickson AW; Habbous S; Wright F; Lofters AK; Jerzak KJ; Das S
JAMA Oncol; 2021 Aug; 7(8):1220-1224. PubMed ID: 34081080
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
[TBL] [Abstract][Full Text] [Related]
10. Survival of Patients With Head and Neck Merkel Cell Cancer: Findings From the Pan-Canadian Merkel Cell Cancer Collaborative.
Nayak AL; Pickett AT; Delisle M; Dingley B; Mallick R; Hamilton T; Stuart H; Talbot M; McKinnon G; Jost E; Thiboutot E; Francescutti V; Samman S; Easson A; Schellenberg A; Merchant S; La J; Vanderbeck K; Wright F; Berger-Richardson D; Hebbard P; Hershorn O; Younan R; Patocskai E; Rodriguez-Qizilbash S; Meguerditichian A; Tchuente V; Kazandjian S; Mathieson A; Hossain F; Hetu J; Corsten M; Tohmé A; Nessim C; Johnson-Obaseki S
JAMA Netw Open; 2023 Nov; 6(11):e2344127. PubMed ID: 37983027
[TBL] [Abstract][Full Text] [Related]
11. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.
Williams SB; Shan Y; Jazzar U; Mehta HB; Baillargeon JG; Huo J; Senagore AJ; Orihuela E; Tyler DS; Swanson TA; Kamat AM
JAMA Surg; 2018 Oct; 153(10):881-889. PubMed ID: 29955780
[TBL] [Abstract][Full Text] [Related]
12. Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
Watson AS; Goutam S; Stukalin I; Ewanchuk BW; Sander M; Meyers DE; Pabani A; Cheung WY; Heng DYC; Cheng T; Monzon JG; Navani V
JAMA Netw Open; 2022 Dec; 5(12):e2245596. PubMed ID: 36480204
[TBL] [Abstract][Full Text] [Related]
13. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
14. Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada.
Dai WF; Beca JM; Croxford R; Isaranawatchai W; Menjak IB; Petrella TM; Mittmann N; Earle CC; Gavura S; Hanna TP; Chan KKW
BMC Cancer; 2020 Apr; 20(1):304. PubMed ID: 32293341
[TBL] [Abstract][Full Text] [Related]
15. Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma.
El Sharouni MA; Aivazian K; Witkamp AJ; Sigurdsson V; van Gils CH; Scolyer RA; Thompson JF; van Diest PJ; Lo SN
JAMA Dermatol; 2021 Feb; 157(2):166-173. PubMed ID: 33355600
[TBL] [Abstract][Full Text] [Related]
16. Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer.
Ethier JL; Desautels D; Robinson A; Amir E; Kong W; Booth CM
JAMA Oncol; 2021 Sep; 7(9):e212140. PubMed ID: 34236387
[TBL] [Abstract][Full Text] [Related]
17. Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).
Forschner A; Eichner F; Amaral T; Keim U; Garbe C; Eigentler TK
J Cancer Res Clin Oncol; 2017 Mar; 143(3):533-540. PubMed ID: 27878363
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
Hodi FS; Lee S; McDermott DF; Rao UN; Butterfield LH; Tarhini AA; Leming P; Puzanov I; Shin D; Kirkwood JM
JAMA; 2014 Nov; 312(17):1744-53. PubMed ID: 25369488
[TBL] [Abstract][Full Text] [Related]
19. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM; Lawson DH; Khan MK; Kudchadkar RR; Buchwald ZS
Lancet Oncol; 2021 Dec; 22(12):1777-1786. PubMed ID: 34780711
[TBL] [Abstract][Full Text] [Related]
20. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
